ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Series 1 Shares - 70million Consolidable or not

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon Jun 30, 2022 6:16pm

159 Views

Post# 34795255

RE:RE:RE:RE:RE:RE:RE:RE:Series 1 Shares - 70million Consolidable or not

OTC Market toda 1563 share traded a smashing day. An enthusiastic investment community with Eugene buying of 600 into that volume. BBall summed it up on June 16 th, we have our deal the Boston group. They have deep pockets and one of them on a nearly daily business with Promis to ensure progress toward the goals. The shares are going to be shrunk by a factor of 60, less supply. Not sure why we need a bod just hand the keys to the Boston group if there running the show.

Now watch for the squeeze to come as they engineered the price to a nearly 5 year low and take out more investors.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market